We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-1.97%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.1B
AUM Growth
+$66.6M
Cap. Flow
-$64.5M
Cap. Flow %
-3.07%
Top 10 Hldgs %
64.85%
Holding
56
New
2
Increased
9
Reduced
13
Closed
4

Top Buys

Rank Stock Value
1
CABO icon
Cable One
CABO
+$43.9M
2
CORT icon
Corcept Therapeutics
CORT
+$21.4M
3
CRM icon
Salesforce
CRM
+$17M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.2M
5
ASML icon
ASML
ASML
+$5.9M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$70M
2
BN icon
Brookfield
BN
+$19.8M
3
NKTX icon
Nkarta
NKTX
+$19.4M
4
ACLX
Arcellx
ACLX
+$15.8M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 51.95%
2 Technology 13.97%
3 Financials 4.89%
4 Communication Services 3.25%
5 Consumer Discretionary 1.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$28.6B
$16.6M 0.79%
770,000
– –
NARI
27
DELISTED
Inari Medical, Inc. Common Stock
NARI
$15.5M 0.74%
213,200
+3,200
+2% +$238K
LVTX
28
DELISTED
LAVA Therapeutics
LVTX
$15.2M 0.73%
3,327,312
– –
TMCI icon
29
Treace Medical Concepts
TMCI
$309M
$13M 0.62%
588,308
– –
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.92B
$12.4M 0.59%
631,627
– –
SILK
31
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$12.4M 0.59%
275,511
– –
OKUR
32
OnKure Therapeutics
OKUR
$168M
$11.5M 0.55%
343,038
– –
ABCL icon
33
AbCellera Biologics
ABCL
$2.12B
$11.1M 0.53%
1,126,915
– –
NKTX icon
34
Nkarta
NKTX
$172M
$10.8M 0.52%
823,200
-1,356,800
-62% -$19.4M
INSP icon
35
Inspire Medical Systems
INSP
$1.74B
$10.8M 0.52%
60,900
+4,500
+8% +$904K
SGEN
36
DELISTED
Seagen Inc. Common Stock
SGEN
$10.3M 0.49%
+75,000
New +$12.2M
RCKT icon
37
Rocket Pharmaceuticals
RCKT
$394M
$10.1M 0.48%
632,822
– –
KNTE
38
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$9.75M 0.46%
815,707
– –
RLYB icon
39
Rallybio
RLYB
$85.8M
$9.13M 0.44%
78,865
-1,763
-2% -$157K
IOBT
40
DELISTED
IO Biotech
IOBT
$8.88M 0.42%
3,277,932
– –
LUNG icon
41
Pulmonx
LUNG
$87.6M
$8.51M 0.41%
510,555
– –
CYT
42
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$7.57M 0.36%
3,940,413
-900,000
-19% -$2.35M
SPRB
43
Spruce Biosciences
SPRB
$129M
$6.18M 0.29%
60,191
– –
BOLT icon
44
Bolt Biotherapeutics
BOLT
$7.78M
$5.48M 0.26%
185,200
-40,000
-18% -$1.66M
KZR
45
DELISTED
Kezar Life Sciences
KZR
$5.15M 0.25%
+59,838
New +$5.81M
DMRA
46
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$4.72M 0.23%
99,912
– –
PHVS icon
47
Pharvaris
PHVS
$2.44B
$4.68M 0.22%
610,000
+90,661
+17% +$1.42M
GRTX
48
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.28M 0.2%
2,459,021
– –
MQ icon
49
Marqeta
MQ
$1.66B
$3.14M 0.15%
110,390
– –
SPNE
50
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$2.99M 0.14%
525,867
-168,810
-24% -$1.07M
1
2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q3 2022 Portfolio in Review

As of Q3 2022, Novo Holdings A/S held 56 positions worth $2.1B, up 3.3% from $2.03B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Novo Holdings A/S withdrew a net $64.5M in Q3 2022, closing 4 positions and reducing 13 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $12.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 59% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in Seagen Inc. Common Stock worth $10.3M.

  • Novo Holdings A/S's largest Q3 2022 buy was Seagen Inc. Common Stock: 75,000 shares worth $10.3M.
  • Novo Holdings A/S added most to Cable One in Q3 2022, an estimated $43.9M increase.
  • Novo Holdings A/S's biggest Q3 2022 reduction was Boston Scientific, cutting an estimated $70M.
  • Novo Holdings A/S fully exited Morphic Holding, Inc. Common Stock in Q3 2022, selling an estimated $12.3M.
  • Novo Holdings A/S's ten largest holdings make up 65% of its $2.1B portfolio in Q3 2022.
  • Novo Holdings A/S opened 2 new positions and closed 4 in Q3 2022.
  • Novo Holdings A/S's portfolio value rose 3.3% quarter-over-quarter to $2.1B.

Based on Novo Holdings A/S's 13F filing for Q3 2022, filed 14 Nov 2022.